What We Do
.png/:/cr=t:0%25,l:0%25,w:100%25,h:100%25/rs=w:600,h:300,cg:true)
Our Services
Attentive Partners works with entrepreneurs, universities, start-ups and venture funds to help technologies, start-ups, and distressed companies achieve market success.
With over 60 years of collective operating experience:
- Attentive Partners can:
- FUND RAISE: Leverage our network to assist in fund raising;
- CONSULT: Augment your team in operational and functional areas;
- CREATE COMPANIES: Launch your promising technology out of the university or clinic;
- ADVISE: Provide experienced independent board membership;
- RESTORE: Re-start, re-cap, re-invigorate distressed companies.
Our Philosophy
With experience in publicly and privately funded healthcare companies, holding roles across numerous functional areas, including c-suite leadership, we recognize that time is a company's most precious asset and that success has a rhythm that pulses from clear milestones linked to value creation.
Our DNA
Strategic Vision
Operational Excellence
Roll Up Our Sleeves Work Ethic
elements
Diligence: Concept-to-Creation
Diligence: Concept-to-Creation
Diligence: Concept-to-Creation
We have spent the last 15 years working together to identify, evaluate and solve unmet clinical and commercial healthcare needs in:
- Dermatology
- Ophthalmology
- Orthopedics
- Cardiovascular
- Neurology
- Metabolic Disorders
- Pulmonology
- Allergy & Immunology
- Gastroenterology
- Female Health
- Aesthetics
- Otolaryngology
Fund Raising
Diligence: Concept-to-Creation
Diligence: Concept-to-Creation
.jpg/:/rs=w:388,h:194,cg:true,m/cr=w:388,h:194)
We've made hundreds of pitch decks and made thousands of pitches, around the globe, to venture capital funds, banks and debt providers, private equity houses, family offices and sovereign funds. Resulting in over $200 million raised with venture capital and private equity and over $250 million in US and European public markets.
Funding from leading groups such as Versant Ventures, SV Life Sciences, The Carlyle Group, Domain Partners, Partners Innovation Fund and Salem Partners.
Clinical Trials
Diligence: Concept-to-Creation
Board Leadership
Where can we collect high quality data? What countries offer reasonable timelines for study approval? Who are the best physicians to work with? Is there a CRO I can trust when my people are not there? How will my investors, my advisors, the FDA or other regulatory agency view my data?
We have answers. We've successfully conducted trials in the US, Canada, Mexico, EU, South America, Asia and Australia.
Board Leadership
Determined & Data Driven
Board Leadership
MYOSCIENCE - The nature of today’s healthcare technology environment requires clear management focus, multidisciplinary problem solving, market awareness, a dose of technical nimbleness and sound direction and support from an engaged Board.
Myoscience pioneered a proprietary platform technology using – Focused Cold Therapy™ – which initially was targeted as a non-toxic alternative to Botox. However, that market was slow to develop, and the technology was confronted by significant regulatory challenges. Armed with insights into an emerging market dynamic the Board recognized the company could pivot and launch into the orthopedic pain management space to address an emerging medical crisis.
This represented a titanic shift in culture, operational management, therapeutic focus and capital structure.
It required a commitment from investors and hands on involvement from Board members to help navigate this new direction. As Board members, Attentive’s partners helped lead the Myoscience team along this journey, at times supplementing management, assisting operations or recruiting talent; whatever was necessary to deliver on expectations.
Product Realization
Determined & Data Driven
Determined & Data Driven
AQUESYS - Taking a product from concept to reality is an intricate, expensive and time-consuming process. It’s not easy and there is a high degree of risk involved. This is a space the partners of Attentive know well. AqueSys (minimally invasive glaucoma implant) is an example of the Attentive team's ability to create companies, strategically develop products, identify, acquire and manage an IP portfolio and to efficiently evolve a concept into a product.
We identified glaucoma treatments (surgery and pharmaceuticals) as a vulnerable gold standard. Patients are notoriously non-adherent with meds glaucoma surgery had not changed significantly in 30 years. We reviewed numerous technologies and ultimately aggregated intellectual property from a private physician in NY and an academic institution in Perth Australia into a company we formed and funded with a venture capital syndicate.
We operated the company from pre-clinical and early pilot to extensive human trials until transitioning management to a new CEO while retaining an active seat on the Board of Directors.
Determined & Data Driven
Determined & Data Driven
Determined & Data Driven
SEBACIA - With acne trials failing left and right and its own trial missing its endpoint, Sebacia was seemingly out of options. Most companies don't recover from missed endpoints. But we had been operating the company since its inception; in fact we sketched the first concept, found and aggregated IP from two esteemed universities and had been in every animal facility and every clinic along the way. We knew it worked. We just had to prove it under the constraints of a pivotal clinical trial.
We dug deep into our data and went back out to every clinical site to uncover what was different this time and what may have led to the unexpected outcome. It turned out that the topical application technique used in most sites varied meaningfully from the technique used to create successful outcomes. So we gathered the information, wrote a 510(k) submission and engaged the FDA with a thorough view of the trial...knowing that it was not approvable. This allowed us to get the great safety profile in front of the reviewers and in subsequent discussions earned tremendous respect from the agency for not hiding bad outcome data; ultimately leading to a creative trial design and FDA clearance.